SCA
LYRA

Sassicaia Capital Advisers’s LYRA THERAPEUTICS INC LYRA Stock Holding History

Sassicaia Capital Advisers’s Portfolio LYRA Stock Details LYRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-200
Closed -$1.26K – 48
2025
Q1 		$1.26K Buy
+200
New +$1.87K ﹤0.01% 27

Other funds holding LYRA

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sassicaia Capital Advisers's LYRA Position: Q2 2025 in Review

Sassicaia Capital Advisers sold out of LYRA THERAPEUTICS INC (LYRA) in Q2 2025, closing a stake of 200 shares — an estimated $1.26K sold.

Sassicaia Capital Advisers first reported a position in LYRA in Q1 2025 and held it in 1 quarter. The position peaked at $1.26K in Q1 2025. 30 funds tracked by Wall St. Rank hold LYRA as of Q2 2025.

  • Sassicaia Capital Advisers reported no remaining LYRA THERAPEUTICS INC position as of Q2 2025 after selling out during the quarter.
  • Sassicaia Capital Advisers sold 200 LYRA THERAPEUTICS INC shares in Q2 2025, an estimated $1.26K.
  • Sassicaia Capital Advisers first reported a position in LYRA THERAPEUTICS INC in Q1 2025 and held it in 1 quarter.
  • Sassicaia Capital Advisers's LYRA THERAPEUTICS INC position peaked at $1.26K in Q1 2025.
  • 30 funds tracked by Wall St. Rank held LYRA THERAPEUTICS INC as of Q2 2025.

Based on Sassicaia Capital Advisers's 13F filing for Q2 2025, filed 13 Aug 2025.